hematopoiet
stem
cell
transplant
hsct
refer
transplant
stem
cell
variou
sourc
bone
marrow
growth
factorstimul
peripher
blood
umbil
cord
blood
treatment
malign
nonmalign
hematolog
autoimmun
genet
diseas
despit
advanc
hsct
transplant
recipi
remain
high
risk
seriou
fatal
complic
develop
consequ
cytoreduct
condit
regimen
use
transplant
immunolog
sequela
follow
engraft
allogen
lymphoid
cell
mediat
graftversushost
respons
patient
immunosuppress
state
infect
secondari
immunosuppress
pulmonari
complic
hsct
common
contribut
consider
morbid
mortal
transplant
recipi
respiratori
failur
common
caus
critic
ill
hsct
three
type
stem
cell
transplant
autolog
syngen
allogen
autolog
transplant
stem
cell
serv
marrow
graft
deriv
patient
syngen
transplant
stem
cell
deriv
genet
ident
twin
allogen
transplant
stem
cell
taken
nonident
sibl
unrel
donor
autolog
syngen
transplant
involv
stem
cell
immunolog
ident
recipi
reaction
graft
host
avoid
allogen
transplant
mismatch
donor
recipi
human
leukocyt
antigen
hla
mediat
graftversushost
diseas
gvhd
graft
reject
decis
type
transplant
perform
base
natur
stage
underli
diseas
whether
suitabl
donor
avail
medic
condit
recipi
advantag
allogen
transplant
autolog
transplant
includ
higher
likelihood
stem
cell
product
free
tumor
contamin
presenc
graftversustumor
activ
main
indic
hsct
treatment
hematolog
malign
solid
tumor
also
use
mani
nonmalign
disord
autoimmun
diseas
rheumatoid
arthriti
system
sclerosi
system
lupu
erythematosu
multipl
sclerosi
amyloidosi
aplast
anemia
hemoglobinopathi
thalassemia
sickl
cell
anemia
genet
disord
inborn
error
metabol
sever
combin
immunodefici
wiskottaldrich
syndrom
one
prerequisit
success
hsct
condit
therapi
transplant
serv
ablat
bone
marrow
erad
tumor
cell
induc
immunosuppress
permit
engraft
prevent
reject
transplant
donor
stem
cell
prepar
regimen
consist
highdos
chemotherapi
without
total
bodi
irradi
tbi
contribut
consider
pulmonari
complic
seen
transplant
irradi
gener
omit
autolog
condit
regimen
concern
late
toxic
secondari
malign
myeloabl
regimen
use
allogen
transplant
consist
cyclophosphamid
administ
either
busulfan
tbi
prophylaxi
allogen
transplant
prevent
gvhd
usual
involv
methotrex
cyclosporin
corticosteroid
vitro
tcell
deplet
graft
infus
minitransplant
nonmyeloabl
reduc
intens
condit
regimen
develop
late
reduc
toxic
profil
associ
myeloabl
regimen
use
primarili
older
patient
multipl
comorbid
may
toler
intens
condit
regimen
less
intens
prepar
regimen
usual
involv
purin
analog
like
fludarabin
conjunct
immunosuppress
chemotherapeut
agent
lowdos
tbi
total
lymphoid
irradi
antithymocyt
globulin
antibodi
prepar
contrast
tradit
myeloabl
prepar
regimen
ablat
host
hematopoiesi
immunosuppress
suffici
allow
engraft
donor
stem
cell
reli
graft
erad
cancer
mean
graftversusmalign
effect
reducedintens
condit
regimen
associ
reduc
transplantassoci
morbid
lower
incid
pulmonari
complic
transplant
pulmonari
complic
hsct
common
incid
one
third
recipi
requir
intens
care
transplant
respiratori
failur
common
caus
critic
ill
pneumonia
lead
infecti
caus
death
hsct
pulmonari
complic
occur
earli
late
posttranspl
cours
due
infecti
noninfecti
etiolog
present
assort
radiograph
find
pulmonari
complic
hsct
also
vari
depend
indic
type
prepar
regimen
preced
stem
cell
transplant
key
differ
pulmonari
complic
autolog
hsct
compar
allogen
hsct
result
fact
cellular
interact
graft
host
cell
essenti
elimin
autolog
transplant
obviat
need
immunosuppress
prevent
treat
gvhd
autolog
transplant
associ
lower
incid
infect
particularli
viral
pneumoniascmv
pneumon
invas
fungal
diseas
opportunist
infect
toxoplasmosi
late
airflow
obstruct
defect
box
relaps
statu
time
transplant
donorrecipi
hla
mismatchingnonident
risk
factor
pulmonari
complic
mortal
hsct
activ
phase
malign
age
greater
year
receipt
hlanonident
donor
marrow
risk
factor
respiratori
failur
hsct
abnorm
pretranspl
pulmonari
function
test
may
predict
subsequ
risk
pulmonari
complic
mortal
reduc
diffus
capac
increas
alveolararteri
oxygen
gradient
independ
risk
factor
interstiti
pneumon
also
independ
associ
increas
earli
mortal
hsct
measur
cytokin
level
plasma
bal
fluid
transplant
may
also
help
predict
patient
risk
posttranspl
pulmonari
complic
patient
elev
level
transform
growth
factor
tgf
b
plasma
tgfa
bal
fluid
granulocytemacrophag
colonystimul
factor
gmcsf
bal
fluid
seem
increas
risk
pulmonari
complic
one
studi
show
elev
pretranspl
tgfb
level
patient
breast
cancer
undergo
autolog
hsct
associ
increas
posttranspl
risk
pulmonari
toxic
hepat
venoocclus
diseas
recipi
allogen
transplant
requir
administr
immunosuppress
agent
transplant
treat
prevent
gvhd
infecti
complic
recipi
autograft
due
chronic
immunosuppress
also
gvhd
caus
immunodefici
state
affect
mucos
surfac
reticuloendotheli
system
bone
marrow
factor
predispos
allogen
recipi
fatal
viral
pneumonia
multidrugresist
bacteria
invas
fungi
similarli
bronchiol
obliteran
almost
exclus
seen
allogen
hsct
specif
pulmonari
complic
associ
hsct
tend
occur
rel
welldefin
time
line
time
intens
cytoreduct
therapi
pattern
immun
reconstitut
follow
influenc
durat
interv
preengraft
phase
ie
day
transplant
character
prolong
neutropenia
break
mucocutan
barrier
accordingli
infecti
complic
expect
primarili
caus
bacteri
fungal
infect
howev
surgic
lung
biopsi
patient
receiv
hsct
radiograph
infiltr
receiv
broadspectrum
antibiot
shown
time
preval
infect
low
pulmonari
complic
primarili
noninfecti
relat
regimenrel
toxic
box
earli
postengraft
period
span
day
transplant
character
persist
impair
cellular
humor
immun
part
determin
exogen
immunosuppress
gvhd
defici
immunoglobulin
loss
protect
alveolar
macrophag
period
neutropenia
usual
resolv
decreas
risk
bacteri
fungal
infect
epidemiolog
infecti
etiolog
thu
chang
involv
predominantli
viral
infect
especi
cytomegaloviru
cmv
routin
use
antivir
cmv
prophylaxi
howev
incid
posttranspl
cmv
pneumonia
decreas
substanti
noninfecti
etiolog
time
includ
engraft
syndrom
delay
pulmonari
toxic
syndrom
late
postengraft
period
begin
day
transplant
time
immun
recoveri
function
variabl
depend
type
hsct
autolog
recipi
recov
rapidli
allogen
recipi
tcell
respons
alloantigen
return
normal
immunoglobulin
level
frequent
remain
depress
viral
pathogen
caus
infect
poor
lymphocyt
function
wherea
inadequ
cellular
immun
result
bacteri
fungal
pathogen
noninfecti
etiolog
primarili
respons
pulmonari
complic
seen
time
includ
chronic
gvhd
drugrel
pulmonari
toxic
bronchiol
obliteran
restrictivefibrot
lung
diseas
boop
overal
risk
pulmonari
infect
patient
receiv
hsct
see
box
depend
multipl
factor
includ
chemotherapi
radiationinduc
neutropenia
lung
injuri
induc
condit
regimen
reject
form
gvhd
local
disrupt
host
defens
intens
pathogen
exposur
addit
hsct
recipi
need
develop
function
immun
system
donorderiv
cell
although
product
red
blood
cell
platelet
granulocyt
occur
soon
hsct
product
lymphocyt
cell
particular
consider
delay
first
year
transplant
seriou
infect
occur
otherwis
uncompl
transplant
histocompat
sibl
donor
match
unrel
donor
histocompat
recipi
gvhd
develop
shift
microbiolog
posttranspl
pneumonia
past
two
decad
larg
part
chang
support
care
posttranspl
period
prophylact
administr
trimethoprimsulfamethoxazol
antivir
antifung
fluoroquinolon
decreas
incid
pneumocysti
carinii
p
jiroveci
pcp
cytomegaloviru
cmv
herp
simplex
hsv
candida
albican
infect
resist
gramneg
gramposit
bacteria
virus
fungi
remain
import
pathogen
box
bacteri
pneumonia
major
caus
morbid
mortal
patient
receiv
hsct
first
month
transplant
notabl
pneumonia
caus
usual
nosocomi
pathogen
incid
bacteri
pneumonia
frequent
due
staphylococcu
streptococcu
speci
respect
one
seri
gramneg
organ
includ
pseudomona
klebsiella
escherichia
stenotrophomona
legionella
acinetobact
serratia
proteu
enterobact
citrobact
speci
organ
includ
enterococcu
rare
anaerob
bacteroid
fusobacterium
speci
commun
pathogen
emerg
immedi
posttranspl
period
haemophilu
influenza
common
isol
follow
streptococcu
pneumonia
legionella
speci
tubercul
atyp
mycobacteri
infect
quit
uncommon
nonendem
area
overal
incid
tuberculosi
allogen
hsct
seri
hong
kong
preval
tb
gener
popul
higher
develop
countri
incid
posthsct
tuberculosi
median
time
infect
onset
late
occur
day
transplant
patient
initi
seen
fever
cough
radiograph
infiltr
standard
treatment
highli
effect
nontubercul
mycobacteri
infect
uncommon
among
hsct
recipi
haemophilum
import
pulmonari
pathogen
hsct
suspect
patient
skin
joint
find
conjunct
pulmonari
infiltr
anoth
rare
caus
bacteri
pneumonia
allogen
patient
nocardia
invas
fungal
infect
lifethreaten
complic
hsct
fungal
diseas
consid
patient
persist
focal
radiograph
abnorm
respond
empir
antibiot
nodular
opac
chest
imag
prolong
neutropenia
corticosteroid
use
histori
prior
fungal
infect
invas
aspergillosi
lead
caus
infecti
death
mortal
allogen
recipi
despit
treatment
incid
invas
aspergillosi
allogen
recipi
bimod
distribut
case
earli
preengraft
period
character
profound
neutropenia
allogen
autolog
recipi
increas
risk
invas
aspergillosi
allogen
patient
experi
second
period
vulner
howev
postengraft
phase
coincid
develop
chronic
gvhd
need
augment
immunosuppress
case
invas
aspergillosi
limit
lung
sinu
cn
involv
also
seen
common
present
symptom
includ
cough
dyspnea
fever
absent
two
third
patient
concomit
pleurit
chest
pain
hemoptysi
clue
radiograph
find
includ
singl
multipl
nodul
caviti
consolid
air
crescent
sign
describ
central
nodul
partial
fulli
surround
air
indict
sequestrum
necrot
lung
tissu
separ
surround
parenchyma
halo
sign
ct
describ
rim
low
attenu
repres
edema
hemorrhag
surround
pulmonari
nodul
present
patient
neutropenia
invas
pulmonari
aspergillosi
intraven
amphotericin
b
voriconazol
caspofungin
avail
therapi
treatment
invas
aspergillosi
despit
treatment
mortal
still
high
adjunct
surgic
resect
local
diseas
may
benefici
select
patient
remain
controversi
candida
cryptococcu
zygomycet
includ
mucor
rhizopu
also
import
pathogen
preval
invas
zygomycot
infect
bear
similar
clinic
cours
aspergillu
zygomycet
angioinvas
lead
thrombosi
pulmonari
infarct
hemorrhag
radiograph
show
cavit
halo
sign
mortal
rate
high
despit
treatment
amphotericin
b
surgic
resect
endem
fungi
encount
less
frequent
histoplasma
coccidioid
usual
occur
reactiv
latent
infect
blastomyc
usual
repres
primari
diseas
emerg
fungal
pathogen
report
caus
pulmonari
infect
includ
fusarium
scedosporium
speci
viral
infect
particularli
cmv
pneumonia
import
caus
morbid
mortal
postengraft
period
mortal
cmv
pneumonia
posttranspl
patient
exceed
advent
combin
therapi
ganciclovir
intraven
immunoglobulin
ivig
improv
surviv
rate
use
prophylaxi
reduc
incid
also
delay
onset
diseas
previous
cmv
infect
occur
first
day
transplant
occur
time
frame
infect
first
day
increas
prophylaxi
regimen
taken
two
approach
univers
prophylaxi
highrisk
patient
defin
period
engraft
preemptiv
treatment
patient
detect
subclin
viremia
pcr
assay
strategi
reduc
risk
earli
cmv
diseas
endors
publish
practic
guidelin
immunosuppress
delay
reconstitut
cytotox
cell
place
patient
receiv
hsct
increas
risk
cmv
pneumonia
highest
risk
seroneg
patient
underw
allogen
transplant
seroposit
donor
risk
factor
includ
viral
shed
site
viremia
chronic
steroid
use
gvhd
patient
chronic
gvhd
particularli
suscept
late
cmv
infect
increas
need
immunosuppress
inher
immunodefici
part
gvhd
process
cmv
pneumonia
nonspecif
clinic
present
includ
fever
nonproduct
cough
hypoxia
chest
imag
demonstr
variou
abnorm
commonli
bilater
interstiti
opac
chest
xray
may
also
focal
diffus
consolid
nodular
opac
groundglass
opac
chest
ct
definit
diagnosi
reli
demonstr
viral
inclus
bodi
lung
tissu
difficult
transbronchi
biopsi
specimen
detect
viru
bal
fluid
shell
vial
assay
polymeras
chain
reaction
viral
cultur
patient
compat
clinic
present
longterm
sequela
includ
bronchiol
obliteran
organ
pneumonia
restrict
lung
diseas
communityacquir
virus
influenza
b
parainfluenza
respiratori
syncyti
viru
adenoviru
also
caus
respiratori
failur
hsct
recipi
collect
recov
patient
receiv
hsct
hospit
acut
respiratori
ill
rsv
common
parainfluenza
viru
infect
caus
upper
lower
respiratori
tract
symptom
present
laryngotrach
croup
bronchiol
pneumonia
incid
allogen
transplant
commonli
serotyp
associ
lower
respiratori
tract
symptom
season
variat
infect
parainfluenza
viru
serotyp
contrast
infect
virus
occur
colder
month
late
fall
earli
spring
respiratori
syncyti
viru
peak
januari
march
often
associ
concomit
otiti
media
sinus
progress
pneumonia
occur
frequent
mortal
untreat
rsv
pneumonia
approach
earli
treatment
ribavirin
ivig
may
decreas
pneumoniarel
mortal
adenoviru
uncommon
caus
pneumonia
isol
patient
hsct
affect
upper
lower
respiratori
tract
well
gastrointestin
genitourinari
system
infect
usual
develop
within
first
month
transplant
present
might
includ
pharyng
tracheiti
bronchiti
pneumon
enter
hemorrhag
cystiti
dissemin
diseas
mortal
pulmonari
involv
may
exceed
viral
infect
includ
hsv
varicella
zoster
viru
human
herpesvirus
absenc
prophylaxi
infect
hsv
occur
transplant
recipi
sever
pneumonia
mortal
incid
hsv
markedli
reduc
acyclovir
prophylaxi
hsv
may
caus
sever
tracheobronch
associ
endobronchi
ulcer
human
herp
viru
associ
idiopath
pneumonia
syndrom
epsteinbarr
viru
infect
usual
manifest
posttranspl
lymphoprolif
disord
usual
bcell
lymphoma
thought
relat
tcell
deplet
suppress
strategi
even
coronaviru
pneumonia
report
hematopoiet
stem
cell
transplant
incid
pcp
pneumonia
markedli
reduc
trimethoprimsulfamethoxazol
prophylaxi
prophylaxi
recommend
time
engraft
month
transplant
allogen
recipi
indefinit
augment
immunosuppress
therapi
chronic
gvhd
pcp
present
approxim
day
transplant
cough
dyspnea
fever
nearli
chest
xray
find
commonli
bilater
interstiti
alveolar
infiltr
diagnost
yield
bal
near
despit
trimethoprimsulfamethoxazol
treatment
mortal
high
pcp
infect
occur
within
first
month
transplant
versu
lateonset
infect
toxoplasma
infect
uncommon
lifetim
incid
patient
prior
cat
exposur
posit
pretranspl
serolog
find
frequenc
much
infect
typic
associ
gvhd
develop
reactiv
first
month
transplant
affect
brain
heart
lung
anoth
rare
caus
pulmonari
infect
hsct
patient
microsporidia
immedi
posttranspl
period
pulmonari
toxic
prior
chemoradiotherapi
pretranspl
condit
regimen
may
manifest
fever
dyspnea
cough
hypoxemia
patchi
diffus
mix
interstiti
alveolar
infiltr
chest
radiographi
prospect
studi
document
efficaci
steroid
set
clinic
practic
prednison
mgkgday
usual
use
treat
lung
toxic
infect
exclud
pulmonari
edema
cardiogen
noncardiogen
common
earli
posttranspl
complic
usual
seen
first
month
transplant
patient
may
underli
cardiac
dysfunct
secondari
previou
treatment
high
dose
cyclophosphamid
anthracyclin
chest
irradi
iv
fluid
given
resuscit
antibiot
mainten
therapi
lead
cardiogen
pulmonari
edema
druginduc
pulmonari
toxic
sepsi
aspir
blood
transfus
cytokin
releas
acut
gvhd
hepat
venoocclus
diseas
induc
noncardiogen
pulmonari
edema
also
report
cardiac
arrest
immedi
infus
autolog
marrow
possibl
secondari
noncardiogen
pulmonari
edema
diffus
alveolar
damag
histologicpatholog
correl
acut
respiratori
distress
syndrom
occur
hsct
usual
set
sepsi
respons
treatment
agent
known
caus
pulmonari
toxic
idiopath
pneumonia
syndrom
ip
noninfecti
form
acut
lung
injuri
defin
widespread
alveolar
injuri
absenc
activ
lower
respiratori
tract
infect
box
publish
seri
report
incid
rang
reflect
rel
difficulti
make
diagnosi
patient
idiopath
pneumonia
may
actual
occult
infect
particularli
cmv
pneumonia
pulmonari
toxic
condit
regimen
report
trend
toward
higher
ip
occurr
allogen
transplant
wherea
other
shown
rel
equival
incid
recipi
allogen
autolog
hsct
respect
among
allogen
recipi
incid
ip
significantli
lower
nonmyeloabl
condit
regimen
tradit
highdos
regimen
consist
idea
ip
result
chemoradiotherapi
risk
factor
includ
older
age
transplant
malign
leukemia
highdos
condit
regimen
total
bodi
irradi
highgrad
acut
gvhd
studi
murin
model
suggest
etiolog
involv
alloimmun
cytokin
storm
myeloabl
condit
recruit
inflammatori
immuneeffector
cell
lung
releas
oxid
proinflammatori
cytokin
result
inflammatori
lung
injuri
median
time
onset
ip
rang
day
transplant
patient
seen
fever
dyspnea
nonproduct
cough
hypoxia
diffus
pulmonari
infiltr
patient
may
progress
respiratori
failur
within
day
mortal
approach
treatment
primarili
support
care
respons
puls
steroid
dose
equival
mgkgday
intraven
methylprednisolon
gener
poor
uncertain
efficaci
novel
agent
etanercept
tnfa
blocker
investig
figur
box
diffus
alveolar
hemorrhag
dah
first
describ
consecut
patient
underw
autolog
hsct
dyspnea
nonproduct
cough
fever
hypoxemia
diffus
alveolar
infiltr
progress
bloodier
return
bal
develop
mortal
retrospect
seri
subsequ
studi
report
lower
incid
signific
differ
note
undergo
autolog
versu
allogen
transplant
risk
factor
includ
age
total
bodi
irradi
transplant
solid
tumor
high
fever
sever
mucos
renal
insuffici
pathophysiolog
well
understood
infect
thrombocytopenia
coagulopathi
seem
directli
implic
autopsi
specimen
show
diffus
alveolar
damag
dah
like
ip
part
spectrum
acut
lung
injuri
induc
condit
chemotherapi
radiat
occult
infect
rapid
immun
system
reconstitut
also
theoriz
contribut
dah
neutrophil
influx
lung
may
accentu
injuri
precipit
hemorrhag
patient
usual
seen
periengraft
period
within
first
month
transplant
patient
seen
late
beyond
day
symptom
radiograph
find
usual
progress
within
h
radiograph
chang
may
preced
clinic
present
sever
day
chest
xray
show
patchi
interstiti
alveolar
infiltr
often
midlow
lung
predomin
becom
diffus
widespread
dah
mortal
support
care
alon
prompt
diagnosi
treatment
crucial
bal
progress
bloodier
aliquot
return
fluid
classic
diagnost
find
figur
treatment
methylprednisolon
mgday
day
follow
steroid
taper
better
outcom
associ
earli
present
autolog
transplant
mortal
versu
lateonset
hemorrhag
box
diagnost
criteria
idiopath
pneumonia
syndrom
engraft
syndrom
character
fever
rash
noncardiogen
pulmonari
edema
occur
coincid
neutrophil
recoveri
engraft
incid
engraft
syndrom
occur
frequent
autolog
hsct
propos
risk
factor
includ
transplant
breast
cancer
use
peripher
blood
rather
bone
marrow
stem
cell
use
granulocyt
colonystimul
factor
mobil
marrow
etiolog
unclear
may
attribut
increas
cytokin
releas
neutrophil
degranul
engraft
dah
rapid
immun
system
reconstitut
also
theoriz
treatment
mgkgday
intraven
methylprednisolon
follow
rapid
taper
interstiti
pneumon
fibrosi
develop
highdos
chemotherapi
autolog
hsct
breast
cancer
refer
delay
pulmonari
toxic
syndrom
dpt
syndrom
often
present
week
month
hsct
gener
respons
corticosteroid
therapi
better
prognosi
ip
patient
seen
dyspnea
exert
nonproduct
cough
fever
pulmonari
function
test
pft
show
restrict
ventilatori
defect
diminish
diffus
capac
dpt
thought
repres
manifest
chemotherapyinduc
lung
injuri
lung
biopsi
show
alveolar
septal
thicken
interstiti
fibrosi
type
ii
pneumocyt
hyperplasia
consist
drug
toxic
moreov
carmustin
bcnu
cyclophosphamid
use
condit
regimen
associ
dpt
known
pneumotox
interstiti
pneumon
manifest
diminish
diffus
capac
total
lung
capac
common
occur
virtual
time
transplant
mani
patient
remain
asymptomat
pft
chang
usual
secondari
treatment
condit
regimen
particularli
contain
carmustin
chronic
airflow
limit
caus
bronchiol
obliteran
common
late
complic
allogen
hsct
except
rare
autolog
hsct
incid
vari
depend
airflow
limit
defin
typic
occur
third
month
posttranspl
associ
underli
chronic
gvhd
risk
factor
includ
older
age
lower
pretranspl
fev
fvc
ratio
low
serum
immunoglobulin
level
methotrex
use
earli
posttranspl
respiratori
viral
infect
etiolog
unclear
strong
associ
gvhd
suggest
immunemedi
injuri
induc
donor
cytotox
cell
host
bronchial
epithelium
report
associ
methotrex
suggest
direct
drugrel
injuri
may
also
play
role
patient
bronchiol
obliteran
seen
insidi
onset
nonproduct
cough
dyspnea
wheez
chest
radiograph
often
normal
highresolut
ct
show
air
trap
hypoattenu
bronchial
dilat
pft
show
airflow
limit
progress
time
also
rate
progress
variabl
rapid
progress
hypercapn
respiratori
failur
death
other
protract
cours
airflow
limit
associ
substanti
attribut
mortal
year
transplant
respect
mortal
higher
subpopul
patient
chronic
gvhd
year
respect
treatment
involv
augment
immunosuppress
case
lung
transplant
azithromycin
suggest
possibl
therapi
box
diagnost
criteria
engraft
syndrom
major
criteria
temperatur
c
identifi
infecti
etiolog
erythrodermat
rash
involv
bodi
surfac
area
attribut
medic
noncardiogen
pulmonari
edema
manifest
diffus
pulmonari
infiltr
consist
diagnosi
hypoxia
hepat
dysfunct
either
total
bilirubin
mgdl
transaminas
level
two
time
normal
renal
insuffici
serum
creatinin
two
time
baselin
weight
gain
baselin
bodi
weight
transient
encephalopathi
unexplain
caus
diagnosi
es
establish
presenc
three
major
criteria
two
major
criteria
one
minor
criteria
es
occur
within
h
engraft
pmn
consecut
day
pulmonari
venoocclus
diseas
pvod
rare
complic
hsct
character
intim
prolifer
fibrosi
pulmonari
venul
lead
progress
vascular
obstruct
increas
pulmonari
capillari
arteri
pressur
process
thought
due
infecti
toxic
injuri
endothelium
chemotherapeut
agent
commonli
associ
pvod
includ
carmustin
mitomycin
c
bleomycin
patient
seen
sever
month
transplant
progress
dyspnea
exert
fatigu
may
also
pleural
effus
right
upper
quadrant
tender
ascit
presenc
pulmonari
arteri
hypertens
pulmonari
edema
normal
pulmonari
arteri
occlus
pressur
strongli
suggest
diagnosi
pulmonari
vasodil
exacerb
pulmonari
edema
anecdot
report
describ
respons
highdos
corticosteroid
posttranspl
lymphoprolif
disord
ptld
anoth
uncommon
complic
allogen
hsct
repres
uncontrol
expans
donorderiv
epsteinbarr
virusinfect
b
lymphocyt
overal
incid
increas
patient
two
follow
risk
factor
unrel
hlamismatch
relat
donor
celldeplet
donor
stem
cell
use
antithymocyt
globulin
patient
usual
seen
within
first
month
transplant
lymph
node
liver
spleen
involv
often
relaps
origin
malign
especi
lymphoma
secondari
lymphoma
lung
involv
seen
case
ptld
often
refractori
standard
chemotherapi
treatment
involv
administr
antibcel
monoclon
antibodi
reduc
immunosuppress
surviv
poor
especi
underli
hematolog
malign
bronchiol
obliteran
organ
pneumonia
boop
occur
late
complic
hsct
sequela
treat
cmv
pneumon
relat
chronic
gvhd
idiopath
incid
adult
allogen
recipi
surviv
beyond
month
often
steroidrespons
lesion
treatment
longterm
surviv
respiratori
failur
occur
commonli
hsct
associ
poor
outcom
seri
consecut
patient
underw
hsct
fred
hutchinson
cancer
research
center
requir
mechan
ventil
surviv
risk
factor
includ
older
age
activ
malign
time
transplant
receipt
hlanonident
allogen
transplant
later
studi
report
surviv
rate
ventil
patient
part
use
peripher
stem
cell
transplant
perhap
earli
institut
noninvas
mechan
ventil
uniformli
fatal
outcom
seen
patient
multisystem
organ
failur
especi
hepat
renal
dysfunct
pulmonari
cytolyt
thrombi
pct
term
describ
vasculopathi
occur
pediatr
allogen
hsct
recipi
character
oblit
arteriopathi
occlus
vascular
lesion
hemorrhag
infarct
entiti
resolv
spontan
without
specif
therapi
pulmonari
alveolar
proteinosi
also
report
revers
caus
respiratori
failur
allogen
hsct
acut
leukemia
approach
evalu
consid
time
frame
pulmonari
problem
occur
radiograph
abnorm
number
individu
patient
factor
exposur
cardiopulmonarytox
drug
pretranspl
condit
regimen
histori
receiv
chest
radiotherapi
current
previou
immunosuppress
regimen
current
previou
prophylaxi
infecti
agent
cmv
statu
donor
recipi
histori
previou
opportunist
invas
fungal
diseas
exposur
cat
bird
mycobacteria
endem
fungi
pulmonari
function
test
abnorm
provid
clue
underli
disord
evid
restrict
ventilatori
defect
pft
follow
chest
ct
assess
subtl
interstiti
diseas
sputum
examin
also
use
identifi
certain
pathogen
invas
diagnost
procedur
usual
reserv
patient
stabl
enough
undergo
procedur
andor
progress
diseas
despit
initi
therapi
chest
radiograph
normal
symptomat
patient
proven
infiltr
lung
diseas
miss
small
nodul
cavit
radiat
pneumon
gvhd
bronchiol
obliteran
chest
ct
sensit
plain
chest
radiograph
often
use
local
guid
invas
diagnost
procedur
diffus
infiltr
common
highli
nonspecif
preengraft
phase
pulmonari
edema
main
caus
noninfecti
process
includ
dah
engraft
syndrom
drug
reaction
engraft
infect
main
caus
diffus
infiltr
typic
chest
radiograph
find
viral
pneumonia
consist
reticulonodular
opac
peribronchi
perivascular
distribut
common
radiograph
find
cmv
pneumon
hsct
parenchym
opacif
multipl
mm
nodul
xray
may
normal
noninfecti
process
postengraft
period
includ
pulmonari
edema
dah
ip
nsip
lymphangit
spread
tumor
chemoradiationinduc
pneumon
focal
infiltr
usual
reflect
infecti
process
higher
likelihood
yield
specif
diagnosi
segment
lobar
infiltr
usual
caus
bacteri
fungal
mycobacteri
infect
local
consolid
accompani
ipsilater
pleural
effus
suggest
bacteri
infect
noninfecti
process
associ
focal
infiltr
includ
hemorrhag
pulmonari
emboli
acut
radiat
pneumon
carcinoma
nodular
infiltr
without
cavit
typic
fungal
infect
aspergillosi
common
often
includ
air
crescent
halo
sign
describ
previous
nocardia
cryptococcu
also
present
nodular
mass
former
commonli
cavit
invas
candidiasi
may
also
present
dissemin
nodul
septic
emboli
nodular
infiltr
feed
pulmonari
vessel
wedgedshap
subpleur
lesion
repres
infarct
pleural
effus
suggest
bacteri
mycobacteri
nocardi
infect
noninfecti
process
associ
pleural
effus
includ
pulmonari
edema
hepat
venoocclus
diseas
pulmonari
infarct
malign
baselin
pft
obtain
hsct
transplant
symptomat
patient
regularli
schedul
interv
highrisk
individu
pretranspl
abnorm
diffus
capac
alveolararteri
oxygen
differ
independ
risk
factor
interstiti
pneumon
death
reduct
pretranspl
fev
strong
predictor
subsequ
develop
cmv
pneumonia
cmvseroposit
allogen
hsct
recipi
transplant
pft
abnorm
commonli
seen
includ
declin
lung
volum
diffus
capac
airflow
posttranspl
reduct
dl
co
found
half
patient
may
persist
month
sever
year
restrict
pattern
report
hsct
recipi
etiolog
restrict
impair
reduc
dl
co
seem
multifactori
includ
toxic
effect
chemoradi
recurr
pulmonari
infect
pulmonari
edema
gener
muscl
weak
idiopath
interstiti
pneumonia
boop
radiograph
next
diagnost
step
patient
worsen
clinic
pictur
usual
invas
test
patient
focal
infiltr
often
given
trial
empir
antibiot
invas
test
perform
sever
day
later
respons
addit
test
discuss
follow
text
aspergillu
common
invas
fungal
infect
posttranspl
patient
noninvas
test
earli
diagnosi
alter
posttranspl
cours
galactomannan
assay
use
monoclon
antibodi
direct
galactomannan
cell
wall
antigen
detect
aspergillu
antigen
elisa
approv
serolog
marker
aspergillu
infect
done
blood
bal
fluid
earli
studi
show
sensit
specif
improv
time
diagnosi
result
obtain
h
oppos
week
standard
cultur
method
serial
monitor
increas
sensit
may
detect
diseas
develop
clinic
symptom
determin
cmv
serolog
statu
recipi
donor
essenti
pretranspl
screen
especi
cmv
diseas
posttranspl
period
one
lethal
infecti
complic
serolog
statu
recipi
oppos
donor
primari
determin
cmv
convers
shell
vial
cultur
monoclon
antibodi
requir
h
test
antigenemia
rapid
standard
semiquantit
inexpens
nucleic
acid
amplif
pcr
dna
extract
infect
leukocyt
also
allow
rapid
diagnosi
detect
infect
week
viral
cultur
becom
posit
week
posit
antigenemia
highli
sensit
cmv
pneumonia
fatal
allogen
recipi
becom
markedli
less
common
use
earli
detect
techniqu
allow
earli
treatment
efficaci
bal
highli
variabl
differ
retrospect
seri
bal
overal
diagnost
yield
complic
rate
modifi
treatment
addit
diagnost
valu
transbronchi
biopsi
conjunct
bal
likewis
controversi
transbronchi
lung
biopsi
superior
bal
alon
diagnosi
malign
may
yield
lung
biopsi
consist
pulmonari
drug
toxic
dad
boop
howev
transbronchi
biopsi
routin
perform
evalu
hsct
patient
pulmonari
complic
attend
risk
nih
review
efficaci
bal
immunocompromis
patient
pulmonari
infiltr
found
procedur
diagnost
case
common
find
infect
common
pulmonari
complic
diagnos
dah
bacteri
pneumonia
rsv
aspergillu
review
bronchoscopi
transbronchi
biopsi
breast
cancer
patient
underw
hsct
found
diagnost
yield
bal
alon
increas
transbronchi
biopsi
common
condit
diagnos
pulmonari
drug
toxic
bacteri
infect
invas
aspergillosi
nih
experi
diagnost
yield
transbronchi
lung
biopsi
less
posit
nondiagnost
neg
find
respect
yield
transthorac
needl
aspir
ttna
ct
fluoroscop
guidanc
high
sensit
common
find
infect
malign
pneumothorax
common
complic
howev
frequent
requir
chest
tube
diagnosi
made
either
bronchoscopi
ttna
surgic
lung
biopsi
either
open
thoracotomi
videoassist
thorascop
approach
consid
next
diagnost
gold
standard
sensit
evalu
pulmonari
infiltr
hsct
effect
surgic
lung
biopsi
patient
outcom
surviv
still
controversi
howev
studi
shown
patient
surgic
lung
biopsi
poorer
outcom
result
rare
led
chang
therapi
patient
frequent
complic
pneumothorax
hemothorax
prolong
mechan
ventil
wound
hematoma
dehisc
incision
neuriti
tumor
recurr
chest
tube
site
procedur
associ
postop
mortal
surviv
day
may
increas
patient
specif
diagnosi
recommend
reserv
open
biopsi
patient
whose
underli
condit
reason
prognosi
result
might
good
chanc
chang
manag
